Keʻena Honua

Ma ʻApelila 25, 2025, ua hoʻolaha ʻo InnoCare Pharma ua hāʻawi ʻia kāna hanauna hou pan-TRK inhibitor zurletrectinib (ICP-723) i ka loiloi mua e ke Center for Drug Evaluation (CDE) o ka China National Medical Products Administration (NMPA), nāna i ʻae i ka New Drug Application (NDA) o z...E heluhelu hou aku»

Ma ʻApelila 25, 2025, ua hoʻolaha ʻo Innovent Biologics ua ʻāpono ka National Medical Products Administration (NMPA) o Kina i ka New Drug Application (NDA) no ka limertinib ma ke ʻano he lāʻau lapaʻau mua no nā poʻe maʻi makua me ka maʻi kanesa māmā non-small cell holomua kūloko a metastatic paha (NSCLC) harbo...E heluhelu hou aku»

Ma ʻApelila 23, ua loaʻa i ka penpulimab a Akeso ka ʻae ʻia ʻana e ka Food and Drug Administration me cisplatin a i ʻole carboplatin a me gemcitabine no ka lāʻau lapaʻau mua o nā pākeke me ka recurrent a metastatic non-keratinizing nasopharyngeal carcinoma (NPC). Ua ʻae pū ka FDA i ka penpulimab-kcqx ma ke ʻano he hewa...E heluhelu hou aku»

Ma Malaki 16, 2025, ua hoʻolaha ʻo Akeso ua ʻae ʻia kāna antibody monoclonal anti-PD-1 i hoʻomohala ponoʻī ʻia, ʻo penpulimab, e ka National Medical Products Administration (NMPA) no ka mālama mua ʻana i ka maʻi nasopharyngeal recurrent a metastatic paha (NPC) i hui pū ʻia ...E heluhelu hou aku»

Ma ʻApelila 24, 2025, ua hoʻolaha ʻo GenFleet Therapeutics ua ʻae ʻo US Food and Drug Administration (FDA) i ka noi lāʻau lapaʻau hou (IND) o GFH375/VS-7375, kahi mea hoʻopaʻa waha KRAS G12D (ON/OFF), no ka hoʻokolohua lapaʻau e mālama ana i nā maʻi puʻupuʻu paʻa holomua me ka hoʻololi ʻana o KRAS G12D. ʻO ke aʻo ʻana...E heluhelu hou aku»

Ma ʻApelila 17, 2025, ua hoʻolaha ʻo Hansoh Pharmaceutical ua loaʻa i ka hui ponoʻī ʻo B7-H3-targeted antibody-drug conjugate (ADC) HS-20093 no ka injection i ka ʻae ʻia e hoʻokomo ʻia ma ke ʻano he Breakthrough-Therapy-Designated Drug e ka National Medical Products Administration (NMPA) o Kina, ...E heluhelu hou aku»

Ma ʻApelila 15, 2025, ua hoʻolaha ʻo InnoCare Pharma ua ʻae ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka China National Medical Products Administration (NMPA) i kahi Noi Lāʻau Lapaʻau Hou (NDA) no kāna hanauna hou pan-TRK inhibitor zurletrectinib (ICP-723) no ka mālama ʻana i nā pākeke a me nā ʻōpio p...E heluhelu hou aku»

I kēia mau lā iho nei, ua hoʻolaha ʻo GenFleet i ka ʻikepili pae II hou loa o ke aʻo ʻana ʻo KROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) i hui pū ʻia me cetuximab no ka lāʻau lapaʻau mua ʻole o ka maʻi kanesa māmā (NSCLC), i loko o kahi hōʻuluʻulu manaʻo lohi ma ka hōʻike waha mini o ka 2025 European Lung Cancer Conf...E heluhelu hou aku»

ʻO PLB1004, i hoʻomohala ʻia e Beijing Avistone Biotechnology Co., Ltd., he mea palekana, koho nui ʻia, a me ka pono o ka irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) i hoʻohana ʻia i ka mālama ʻana i ka maʻi kanesa non-small-cell-lung (NSCLC). Ma ka lā 9 o ʻApelila, 2025, ua hoʻolaha ʻo National Medical Products Admi...E heluhelu hou aku»

Ma Malaki 13, 2025, ua paʻi ka puke pai honua kiʻekiʻe ʻo Nature Medicine i ka hoʻokolohua B7-H3 targeting antibody drug conjugate (ADC) YL201 Phase 1/1b a MediLink. Ua komo pū ka hoʻokolohua i kahi ʻāpana hoʻonui dose (phase 1) a me kahi ʻāpana hoʻonui dose (phase 1b). He 312 mau maʻi i kākau inoa ʻia ma...E heluhelu hou aku»

Ma Malaki 21, 2025, ua hoʻolaha ʻo Immunofoco ua ʻae ʻia kāna hana lapaʻau cell CAR-T autologous EpCAM i hoʻomohala kūʻokoʻa ʻia, ʻo IMC001, e ke Center for Drug Evaluation (CDE) ma lalo o ka National Medical Products Administration (NMPA) ma Kina no kāna ʻelua Investigational New D...E heluhelu hou aku»

Ma Malaki 31, 2025, ua hoʻolaha ʻo Innovent Biologics ua hāʻawi ke Center for Drug Evaluation (CDE) o ka National Medical Products Administration (NMPA) o Kina i ka Breakthrough Therapy Designation (BTD) no IBI363, kahi protein fusion antibody bispecific PD-1/IL-2α-bias mua loa o ka papa, ma ke ʻano he monotherapy no...E heluhelu hou aku»